Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

H. Lundbeck A/S16 enrolled

Overview

The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) is a safe treatment for patients who have suffered an acute ischemic stroke.

Acute ischemic stroke is a major cause of death and severe disability. There is only one approved pharmacological treatment, Alteplase, which has to be administered within 3 hours from symptom onset. Consequently, only about 2-3% of patients world wide with ischemic strokes are treated. The naturally occurring hormone, erythropoietin (EPO), is able to protect various neuronal tissues from ischemic injury and is beneficial in animal models of acute ischemic stroke. However, treatment of stroke with EPO is undesirable due to its ability to stimulate production of red blood cells and to promote the blood to coagulate. Lu AA24493 is a modified (carbamylated) version of EPO, neuroprotective but without the haematopoietic side effects. Lu AA24493 is developed for treatment of patients with acute ischemic stroke. In this safety study of single doses with Lu AA24493, patients will receive Lu AA24493 within 12-48 hours from symptom onset.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Acute Ischemic Stroke

Interventions

Lu AA24493 (CEPO)DRUG

0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

PlaceboDRUG

Vials with solution for IV infusion

Eligibility

Sex: ALLMin age: 50 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 50 and 90 years * Clinical diagnosis of acute ischemic stroke * Measurable stroke-related deficit * Patient is stable * Treatment can be initiated between 12 hours and 48 hours after the onset of stroke * Expected hospital stay of at least 72 hours after study medication * If female then not of childbearing potential Exclusion Criteria: * Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm * Treated with a thrombolytic \<24 hours (if \>24 hours excluded ICH then eligible) * Score \>0 on the NIHSS item 1a * Pre-stroke mRS score \>1 * Uncontrolled hypertension * Previous treatment with erythropoietin * Clinically significant abnormal ECG * Cerebral pathology * Received or donated blood within previous 3 months

Locations (5)

FI004

Helsinki, Finland

FR002

Paris, France

NL005

Breda, Netherlands

SG003

Singapore, Singapore

GB001

Glasgow, United Kingdom

Outcomes

Primary Outcomes

National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS)

Time frame: Baseline, Day 7, Day 30; for NIHSS also Day 2 and 3

Secondary Outcomes

Pharmacokinetics, immunogenicity and mechanistic biomarkers (S-100b, glial fibrillary acidic protein (GFAP), matrix metalloproteinase 9 (MMP-9))

Time frame: Baseline, Day 1-4, Day 7 and Day 30

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.